Back

Poly(allylamine)-tripolyphosphate polymeric nanoparticle as an NLRP3-dependent systemic adjuvant for the vaccine development

Rizzo, G. P.; Sanches, R. C.; Chavero, C.; Bianchi, D. S.; Apuzzo, E.; Herrera, S. E.; Agazzi, M. L.; Keitelman, I. A.; Trevani, A. S.; Oliveira, S. C.; Azzaroni, O.; Smaldini, P. L.; Docena, G. H.

2024-07-04 immunology
10.1101/2024.07.01.601578 bioRxiv
Show abstract

Nanotechnology plays a crucial role in vaccine development. It allows the design of functional nanoparticles (NPs) that can act both as antigen carriers and as adjuvants to enhance the immune response. The present study aims to evaluate complex coacervate-like NPs composed of poly(allylamine hydrochloride) (PAH) and tripolyphosphate (TPP) as a safe vehicle and adjuvant for systemic vaccines. We investigated the activation of different antigen-presenting cells (APCs) with NPs and their adjuvanticity in Balbc/c and different KO mice that were intraperitoneally immunized with NP-OVA. We found that NPs increased the expression of CD86 and MHCII and promoted the production and secretion of interleukin-1{beta} (IL-1{beta}) and IL-18 through the inflammasome NLRP3 when macrophages and dendritic cells were co-incubated with LPS and NPs. We evidenced an unconventional IL-1{beta} release through the autophagosome pathway. The inhibition of autophagy with 3-methyladenine reduced the LPS/NPs-induced IL-1{beta} secretion. Additionally, our findings showed that the systemic administration of mice with NP-OVA triggered a significant induction of serum OVA-specific IgG and IgG2a, an increased secretion of IFN-{gamma} by spleen cells, and high frequencies of LT CD4+IFN-{gamma}+ and LT CD8+IFN-{gamma}+. Our findings show that NPs promoted the inflammasome activation of innate cells with Th1-dependent adjuvant properties, making them valuable for formulating novel preventive or therapeutic vaccines for infectious and non-infectious diseases. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=193 HEIGHT=200 SRC="FIGDIR/small/601578v2_ufig1.gif" ALT="Figure 1"> View larger version (39K): org.highwire.dtl.DTLVardef@60d382org.highwire.dtl.DTLVardef@de17b2org.highwire.dtl.DTLVardef@e5aebeorg.highwire.dtl.DTLVardef@13347b0_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Journal of Controlled Release
39 papers in training set
Top 0.1%
14.5%
2
Nanoscale Advances
13 papers in training set
Top 0.1%
12.5%
3
Advanced Functional Materials
41 papers in training set
Top 0.2%
10.6%
4
Biomaterials Science
21 papers in training set
Top 0.1%
8.3%
5
ACS Nano
99 papers in training set
Top 0.8%
4.6%
50% of probability mass above
6
Biomaterials Advances
20 papers in training set
Top 0.1%
4.0%
7
ACS Biomaterials Science & Engineering
37 papers in training set
Top 0.2%
3.6%
8
ACS Applied Bio Materials
21 papers in training set
Top 0.2%
2.1%
9
Journal of Biomedical Materials Research Part A
18 papers in training set
Top 0.2%
1.9%
10
Small
70 papers in training set
Top 0.6%
1.5%
11
Molecular Pharmaceutics
16 papers in training set
Top 0.3%
1.3%
12
International Journal of Molecular Sciences
453 papers in training set
Top 9%
1.3%
13
ChemBioChem
50 papers in training set
Top 0.8%
1.2%
14
Advanced Biology
29 papers in training set
Top 0.6%
1.2%
15
ACS Applied Materials & Interfaces
39 papers in training set
Top 0.7%
1.2%
16
Advanced Materials
53 papers in training set
Top 1%
1.1%
17
Frontiers in Immunology
586 papers in training set
Top 6%
1.1%
18
ACS Infectious Diseases
74 papers in training set
Top 0.9%
1.0%
19
PLOS ONE
4510 papers in training set
Top 62%
1.0%
20
Scientific Reports
3102 papers in training set
Top 70%
0.9%
21
Advanced Therapeutics
15 papers in training set
Top 0.3%
0.9%
22
Pharmaceutics
21 papers in training set
Top 0.3%
0.9%
23
Frontiers in Plant Science
240 papers in training set
Top 5%
0.9%
24
Molecules
37 papers in training set
Top 2%
0.8%
25
Advanced Science
249 papers in training set
Top 19%
0.8%
26
iScience
1063 papers in training set
Top 31%
0.8%
27
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.9%
0.7%
28
The Journal of Physical Chemistry B
158 papers in training set
Top 2%
0.7%
29
Vaccines
196 papers in training set
Top 3%
0.7%
30
Neuroscience & Biobehavioral Reviews
43 papers in training set
Top 1%
0.7%